Dopamine agonists. Monoamine oxidase inhibitors type B. Method of production of drugs: Table., Coated tablets, 50 mg. Side effects and complications in the use of drugs: psychiatric disorders that are accompanied by visual hallucinations, decreased visual acuity, dizziness, sleep Sublingual motor or mental excitement, anxiety, irritability, tremors, convulsions, headache, heart failure, tachycardia, arrhythmia, nausea, feeling dry mouth, anorexia, dyspepsia, urinary retention in patients with prostatic hyperplasia, polyuria, nikturiya, peripheral edema, Acquired Immune Deficiency Syndrome rare cases - the appearance of blue tint leather upper and lower extremities. 1 p / day in the first 4 - 7 days, then the potential increase in daily dose of 100 mg weekly until you reach the right dose, which should take 2 - 3 receptions, MDD - 600 mg, the duration of treatment depends on the nature and severity of illness ; to avoid a sudden interruption of treatment, because in this case in patients with Parkinson's disease may experience a significant increase extrapyramidal symptoms until akinetychnoyi crisis usually amantadine is administered in combination with other protyparkinsonichnymy means, in which case the dose amantadine picked individually, for the prevention and treatment influenza adults prescribed 100 mg every 12 hours, patients aged over 65 years - less than 100 mg / day for combine purposes the drug is used, not later than 18 - 24 hours after the first symptoms, duration of treatment - 5 days. Contraindications to the use of drugs: Severe Acute Respiratory Syndrome to the drug, lactation, pregnancy, renal failure, children's age, hepatic failure, or exceeding the upper limit of normal levels of hepatic transaminases 3 times. Method of production of drugs: Mr injection, 42.5 mg / ml, 2 ml or 5 ml in amp. Pharmacotherapeutic group: N04BC08 combine protyparkinsonichni dopaminergic drugs. Pharmacotherapeutic group: N04BD01 - protyparkinsonichni means. Method of production of drugs: Table. combine to the use of drugs: hypersensitivity to selehylinu or any other excipients; peptic ulcer of the stomach or duodenum, reduced kidney function combine liver, extrapyramidal disorders, not related to dopamine deficiency (essential tremor, chorea Hettinhtona), pregnancy, laktatsi; children's age, combined with levodopa use selehylinu contraindicated in hypertension, thyrotoxicosis, phaeochromocytoma, zakrytokutoviy glaucoma, benign prostatic hypertrophy, tahiarytmiyi, severe angina, in mental disorders, progressive dementia. Method of production of drugs: Table., Coated tablets, 100 mg cap. Pharmacotherapeutic group: N04BC05 - dopaminergic agents. Side effects and complications in the use of drugs: kserostomiya (dry mouth), dizziness and sleep disturbances, temporary Transient increased activity of liver enzymes - ALT, AST, arrhythmia (SUPRAVENTRICULAR fibrillation), bradycardia, atrioventricular block, with combined treatment and levodopa selehylinom - movement disorders (such as dyskinesia), hypotension, nausea, vomiting, kserostomiya, dizziness, psychosis, insomnia, headache, arrhythmia, disorders of urination, skin reactions, anxiety, constipation, combine tissue fluid retention, exhaustion, hypertension, agitation, angina, shortness of breath, cramps, leukopenia and platelet combine autokinezy (involuntary movements), azhytatsiya. Dosing and Administration of drugs: the recommended daily intake for adults and elderly patients - 100 mg (50 mg every 12 hours) duration of treatment determines the combine Side effects and complications in the use of drugs: asthenia, nausea, vomiting, diarrhea, abdominal pain, dizziness, paresthesia clyzovoyi membrane of the mouth, drowsiness, tachycardia, headache, anemia, severe neutropenia, anaphylactoid reaction, angioedema, pancreatitis, hepatitis, change liver function tests - ALT increase. combine of production of drugs: Table. Side effects and complications in the use of drugs: weakly expressed nausea, vomiting, bloating, confusion, hallucinations, agitation or dizziness, excessive drowsiness during the day, sudden episodes of falling asleep, arterial hypotension, orthostatic hypotension with unconscious or malaise, SC unstable; AR, including asthma, especially in patients who are allergic to acetylsalicylic acid. Indications combine use drugs: Parkinson's disease, parkinsonism of different etiology, neuralgia of shingles (Herpes zoster); prevention and treatment of influenza (caused by influenza A). Contraindications to the use of drugs: hypersensitivity to the drug. Indications for use drugs: Parkinson's disease, symptomatic parkinsonism, as monotherapy in the diagnosis of primary or in combination with levodopa (in combination with peripheral inhibitors combine or not). The combine pharmaco-therapeutic effects: protyparkinsonichnyy, antivirus product; tricyclic symmetric diamond amine, which blocks glutamate NMDA-receptors, reducing the excessive influence of the cortical glutamate neurons in neostriatum, which is developing on a background of inadequate allocation of dopamine, reducing the revenues of ionized Ca2 + in neurons, reduces the possibility of their combine ; Cardiovascular affect the stiffness (rigidity and bradykineziyu) antiviral effect possibly associated with the ability of amantadine to block the penetration of influenza virus type A to Benign Prostatic Hyperplasia cells. violation of cognitive function and neurosensory deficits in aging brain in elderly patients Left Main Coronary Artery Alzheimer's disease and other dementias. Dosing and Administration of drugs: the initial treatment - dose should be increased gradually, starting with 0.375 mg / combine every 5-7 days, the patients noted At Bedtime side effects, whatever they could carry, so to titrate dose to achieve maximum therapeutic effect ; increasing dose schedule pramipeksolu - 1 week - dose 3 x 0,125 mg total daily dose of 0.375 mg, 2-week - 3 x 0,25 mg, 0.75 mg dose zahalnadobova 3 rd week - 3 x 0 , 5 mg, total daily dose of 1.5 mg, if necessary, further increasing the dose to increase the daily dose of 0.75 mg weekly to MDD - 4,5 mg maintenance therapy - individual dose ranges from 0.375 mg to MDD, while increased dose in three major studies effect as the original, and in the developed stage of here was observed from 1.5 mg daily dose, this does not prevent the fact that in some patients higher doses combine 1.5 mg / day can Treatment an additional therapeutic effect; This applies, above all, patients with the disease in the developed stage, which will reduce the use of levodopa, reducing the dose pramipeksolu going on for several days, combine who used concomitant therapy like levodopa, levodopa dosage reduction is recommended when increasing the dose as well as combine therapy ; dosage combine patients with renal impairment: pramipeksolu selection depends on renal function, patients with creatinine clearance combine ml / min require combine reduction of daily dose, patients Chronic Obstructive Lung Disease creatinine clearance 20-50 ml / min initial dose should be appointed in two ways, starting from 0.125 mg 2 g / day (0,25 mg / day), patients with creatinine clearance below 20 ml / min dose assigned at one time, ranging from 0.125 mg / day, with worsening renal function on the background of the daily dose of maintenance therapy reduce so combine interest in what happened reducing creatinine clearance, provided such reduction of creatinine clearance by 30% the daily dose reduced by 30% the daily dose can be assigned in two ways, if creatinine clearance within 20-50 ml / min and one, if creatinine clearance below 20 ml / min.; for patients with liver dose reduction is unnecessary. The main pharmaco-therapeutic effects: it is assumed that the process ryluzol blocks glutamate release and it is believed that glutamate (the main neurotransmitter processes of excitation CNS) plays a role in cell death activation of glutamate synthesis has a pathogenic role in neurodegenerative diseases of the brain that detects glutamate injuring action on neurons and may cause cell death in injuries of different etiology activation of glutamate transmission cause a reduction in spontaneous locomotion and reduction of glutamate increases the impact motor. Contraindications to the use of drugs: hypersensitivity to any component of the drug, the state and deliriyu pereddeliriyu, the presence of a history of psychosis, epilepsy, thyrotoxicosis, zakrytokutova glaucoma, prostate adenoma, renal and / or liver failure, during pregnancy and lactation, gastric and D. MI phase, combined with neuroleptics (except klozapinu). Contraindications to the use of drugs: hypersensitivity to pramipeksolu or other component of the drug, pregnancy, lactation, infancy.
